1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Toxoplasmosis - Pipeline Review, H2 2016

Toxoplasmosis - Pipeline Review, H2 2016

  • December 2016
  • -
  • Global Markets Direct
  • -
  • 39 pages

Toxoplasmosis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis – Pipeline Review, H2 2016, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.

Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.


Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.Toxoplasmosis.

Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Toxoplasmosis - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Toxoplasmosis Overview 6
Therapeutics Development 7
Pipeline Products for Toxoplasmosis - Overview 7
Pipeline Products for Toxoplasmosis - Comparative Analysis 8
Toxoplasmosis - Therapeutics under Development by Companies 9
Toxoplasmosis - Therapeutics under Investigation by Universities/Institutes 10
Toxoplasmosis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Toxoplasmosis - Products under Development by Companies 13
Toxoplasmosis - Products under Investigation by Universities/Institutes 14
Toxoplasmosis - Companies Involved in Therapeutics Development 15
AbbVie Inc 15
Turing Pharmaceuticals AG 16
Toxoplasmosis - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
CCP-010 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
RandD Progress 25
Small Molecule to Inhibit Histone Deacetylase for Toxoplasmosis and Other Parasitic Diseases - Drug Profile 26
Product Description 26
Mechanism Of Action 26
RandD Progress 26
Small Molecules for Toxoplasmosis - Drug Profile 27
Product Description 27
Mechanism Of Action 27
RandD Progress 27
Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile 28
Product Description 28
Mechanism Of Action 28
RandD Progress 28
Small Molecules to Inhibit DHFR for Toxoplasmosis - Drug Profile 29
Product Description 29
Mechanism Of Action 29
RandD Progress 29
toxoplasmosis vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
RandD Progress 30
toxoplasmosis vaccine - Drug Profile 31
Product Description 31
Mechanism Of Action 31
RandD Progress 31
toxoplasmosis vaccine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
RandD Progress 32
toxoplasmosis vaccine - Drug Profile 33
Product Description 33
Mechanism Of Action 33
RandD Progress 33
TRP-004 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
RandD Progress 34
TRP-012 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
RandD Progress 35
TRP-013 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
RandD Progress 36
Toxoplasmosis - Dormant Projects 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables
Number of Products under Development for Toxoplasmosis, H2 2016 7
Number of Products under Development for Toxoplasmosis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Toxoplasmosis - Pipeline by AbbVie Inc, H2 2016 15
Toxoplasmosis - Pipeline by Turing Pharmaceuticals AG, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Toxoplasmosis - Dormant Projects, H2 2016 37

List of Figures
Number of Products under Development for Toxoplasmosis, H2 2016 7
Number of Products under Development for Toxoplasmosis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Targets, H2 2016 18
Number of Products by Stage and Targets, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 20
Number of Products by Molecule Types, H2 2016 23
Number of Products by Stage and Molecule Types, H2 2016 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016’, provides in depth ...

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline ...

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.